Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$139.14M+149.44%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Chig Fung Cheng
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,796
- Beta
- 0.43
- Country
- HK
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.06
Financials
Revenue
$139.14M+149.4%Net Income
$7.96M+42.7%EBITDA
$3.97MFree Cash Flow
$3.30MEPS (diluted)
$0.05+0.0%Shares Outstanding (diluted)
174.57M+43.5%Operating Expenses
$62.63MCash & Debt
$1.38BReturn of Capital
$0.00Revenue by Segment (annual)
$153.71MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $549.96M | $458.12M | $2.65 |
| 2024 | $630.20M | $37.73M | $0.22 |
| 2023 | $838.00M | $100.78M | $0.60 |
| 2022 | $426.41M | $-360.83M | $-2.15 |
| 2021 | $356.13M | $-194.65M | $-1.25 |
| 2020 | $228.37M | $-125.95M | $-4.50 |
| 2019 | $204.89M | $-106.02M | $-0.80 |
| 2018 | $214.11M | $-74.81M | $-0.55 |
| 2017 | $241.20M | $-26.74M | $-0.22 |
| 2016 | $216.08M | $11.70M | $0.10 |
| 2015 | $178.20M | $7.99M | $-0.32 |
| 2014 | $87.33M | $-32.82M | $-0.33 |
| 2013 | $45.97M | $5.92M | $0.06 |
| 2012 | $22.37M | $3.64M | $0.04 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from HCM's reported EPS growth of 39.5% a year over 13 years. Historical EPS growth of 39% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $9.91
- Implied price
- $49.55
- Return from $14.20
- 28.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $24.63 — today's price is already 42.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 1 | 3 | 5 | 7 | 9 |
|---|---|---|---|---|---|
| 20.0% | -14.1% | 7.0% | 18.5% | 26.8% | 33.3% |
| 25.0% | -10.5% | 11.5% | 23.5% | 32.0% | 38.9% |
| 30.0% | -6.9% | 15.9% | 28.4% | 37.3% | 44.4% |
| 35.0% | -3.4% | 20.4% | 33.3% | 42.6% | 50.0% |
| 40.0% | 0.2% | 24.8% | 38.3% | 47.9% | 55.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
65-7.14%Social Signal Score
Mentions (14)
- Newsseekingalpha.com·5d ago·Positive
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. LXRX anticipates NDA resubmission for ZYNQUISTA in T1D by Q4 2026, contingent on STENO1 safety data. Top-line results from the pivotal phase 3 SONATA-HCM trial for sotagliflozin in HCM are expected in Q1 2027.
View source ↗ - Newsglobenewswire.com·7d ago·Neutral
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer — Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —
View source ↗ - Newsglobenewswire.com·8d ago·Neutral
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors.
View source ↗ - Newsglobenewswire.com·12d ago·Negative
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.
View source ↗ - Newsmarketbeat.com·15d ago·Positive
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027.
View source ↗ - Newsmarketbeat.com·32d ago·Negative
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfront payment, according to Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng.
View source ↗ - Newsproactiveinvestors.co.uk·33d ago·Negative
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday's 179.5p close following news that GSK will receive exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise H…
View source ↗ - Newsreuters.com·33d ago·Negative
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker said on Thursday.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy — Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English —
View source ↗ - Newsglobenewswire.com·36d ago·Positive
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of th
View source ↗ - Newsglobenewswire.com·39d ago·Negative
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China
View source ↗ - Newsseekingalpha.com·47d ago·Neutral
…cals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last update. Sotagliflozin, targeting HCM and T1D, is the primary value driver; the pivotal SONATA-HCM Phase III readout is expected in 2027, and an NDA re-filing for T1D before year-end. Regulatory and commercialization risks arguably outweigh clinical risk, especially for T1D, as the company would have to commit considerable resources to commercialization to maximize …
View source ↗ - Newsproactiveinvestors.co.uk·49d ago·Negative
HUTCHMED shares rise as lung cancer drug trial hits key targets Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in combination with AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Tagrisso in patients with a form of non-small cell lung cancer whose disease had wors…
View source ↗ - Newsglobenewswire.com·50d ago·Positive
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® — First global Phase III trial to show significant progression-free and overall survival benefits in this setting —
View source ↗
Earnings
Thu, Mar 4(in 5 months)
Consensus estimate $0.21 per share
Typical surprise +78.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.05 vs $0.14miss
- Thu, Jul 2$0.05 vs $-0.36beat
- Thu, Mar 5$0.00 vs $2.50miss
- Thu, Aug 7$2.60 vs $1.46beat
- Wed, Jul 2$1.35 vs $-0.32beat
- Wed, Mar 19$0.07 vs $0.04beat
Estimates and results for HCM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HCM officers and directors.
No open-market trades in the recent filings. All 52 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
52 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HCM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.